DAC vs No-DAC: Which I Picked and Why is best understood as a clinical decision topic, not a shortcut. The evidence, pharmacy source, dose plan, contraindications, and follow-up matter more than any single success story online.
Last October, I was sitting in my prescriber’s office in Scottsdale watching Dr. Reeves pull up my 6-week bloodwork on his monitor. He turned the screen so I could see the IGF-1 line: 232. “That’s higher than I want you running long-term,” he said, tapping the number with his pen. “We’re going to switch you off the DAC.” I’d been on CJC-1295 with DAC for about four months at that point, and honestly, I didn’t want to hear it. The stuff was working. But he was right, and the next ten months proved it.
The DAC versus no-DAC question gets argued in peptide forums with the intensity of a religious dispute and the precision of a coin flip. I’ve now run both versions for several months each under the same prescriber. Here’s the actual decision framework he used, what my labs showed, and why I ultimately landed where I did.
Compliance frame: CJC-1295 in both DAC and no-DAC forms is not FDA-approved for any human indication. It is accessed through 503A compounding pharmacies for individual patient prescriptions prepared by licensed pharmacies based on clinical judgment. The FDA placed CJC-1295 on the 503A bulks list under review in 2023. This is not medical advice.
Two Versions of the Same Receptor Signal
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotrophs and tells them to release growth hormone. Simple enough. The complication is that it comes in two forms.
No-DAC is the peptide as designed. Half-life of roughly 30 minutes. You inject it, it amplifies the natural GH-releasing signal briefly, and then it clears. Think of it like turning the volume knob up for one song, then back to normal.
With DAC is the same peptide modified with a drug affinity complex that binds reversibly to serum albumin. That albumin binding extends the half-life to 6 to 8 days. One injection produces a sustained elevation in GH-releasing signal across most of a week. Same volume knob, but now someone taped it at 7 and walked away.
Both hit the same receptor. The difference is duration, not mechanism. And that distinction matters more than most people realize.
Why the GH Pattern Isn’t a Minor Detail
Here’s the thing about growth hormone: your body releases it in pulses. The biggest pulses come during the first cycles of slow-wave sleep. This pulsatile pattern isn’t arbitrary. GH receptors downregulate when they’re exposed to a constant signal (the same way you stop smelling your own cologne after twenty minutes). Pulsatile release also appears more efficient at driving the downstream effects people actually care about, including IGF-1 production and tissue repair signaling.
No-DAC, dosed at night alongside ipamorelin, amplifies the natural nighttime GH pulse without flattening the overall rhythm. The peak goes higher than baseline, but the timing stays intact.
DAC creates what some clinicians call the “GH bleed,” a sustained elevation in GH-releasing signal across the entire week. Natural pulses still fire on top of this elevated baseline, but the pattern shifts from clean pulses to something more like a plateau with bumps on top.
Whether that bleed is a feature or a flaw depends entirely on context.
How My Prescriber Thinks About the Choice
Dr. Reeves defaults to no-DAC for general adult peptide therapy. His reasoning, as he laid it out for me:
- It preserves the pulsatile pattern, which appears more biologically natural and may reduce the risk of receptor desensitization.
- It’s far easier to titrate. The shorter half-life means dose adjustments take effect within days, not weeks. If something goes sideways, you’re not waiting around for a compound with a week-long tail to clear.
- Lower risk of fluid retention and other GH-related side effects, because average IGF-1 elevation tends to be more modest.
- Convenient to stack with ipamorelin in the same nightly injection.
He reserves DAC for specific scenarios: patients who genuinely cannot adhere to a daily injection schedule for legitimate lifestyle reasons; patients in a recovery window from significant injury or surgery, where a sustained IGF-1 elevation may outweigh the cost of a blunted pulse pattern; and patients who’ve done well on no-DAC and want to test whether a sustained pattern offers incremental benefit, with the explicit understanding that lab monitoring needs to be tighter.
He does not start patients on DAC by default. He moves them there when the case is specific. I think that’s the right call, and I arrived at that opinion the hard way.
Four Months on DAC: Fast Results, Then a Warning Sign
I went the opposite of his usual order. I started on DAC because I liked the idea of two injections a week instead of five. Convenience won. (It usually does, until it doesn’t.)
CJC-1295 with DAC at 2 mg twice weekly, plus nightly ipamorelin at 200 mcg. IGF-1 went from a baseline of 128 to that 232 reading at the 6-week lab.
Body composition shifted quickly. I dropped about 2 percent body fat in the first 8 weeks. Sleep got noticeably deeper. Recovery from training improved in a way I could feel by the second week.
Then around week 6, I noticed mild ankle puffiness at the end of the day. Some morning hand stiffness for the first 10 minutes after waking, the kind where you open and close your fists a few times before it clears. Dr. Reeves identified it as early fluid retention and dropped the DAC dose to 1.5 mg twice weekly. The puffiness resolved within two weeks.
The IGF-1 settled at 198. Still higher than he wanted for sustained dosing. That’s when the switch happened.
Ten Months on No-DAC: The Boring Truth
CJC-1295 no-DAC at 100 mcg combined with 200 mcg ipamorelin, 5 nights per week, both in the same syringe.
IGF-1 settled into a 180 to 195 range and held steady across quarterly labs.
Body composition continued to improve, just more slowly. The fast initial gains I’d seen on DAC tapered into a steady, undramatic trajectory. The cumulative result at 12 months on the combined protocol was equivalent to, or slightly better than, what I’d achieved on DAC alone. No side effects. No puffiness. No morning stiffness.
Sleep stayed deeper. Recovery stayed faster. And I stopped worrying about my labs.
That last part sounds minor. It isn’t. There’s a real psychological cost to running a protocol where you’re always slightly above the line your doctor drew, wondering if today’s the day something tips. On no-DAC, I’m comfortably in the range and not thinking about it. That matters.
Why I’m Staying Put
Three reasons, in order of importance.
The fluid retention told me something. Even though it was mild and resolved quickly, it was a signal about how my system handles a sustained GH-releasing stimulus. The pulsatile pattern of no-DAC has not produced anything equivalent in over 9 months. My body likes the rhythm. I’m not going to argue with it.
The IGF-1 trajectory is calmer. On DAC, my numbers were always a little hot. On no-DAC, I’m where my doctor wants me and I don’t need to think about it between labs.
The principle. Hormone signaling is pulsatile for a reason. Preserving that pattern feels like the right default unless there’s a compelling, specific reason to override it. “I don’t want to inject every night” is a preference, not a clinical rationale. (I say this as someone who initially made that exact argument.)
When DAC Might Still Be the Right Call
I’m not making a blanket case against DAC. It could be appropriate for someone with a documented adherence issue that isn’t going to resolve, a specific post-surgical recovery window, or a clinical context where sustained IGF-1 elevation is the deliberate goal with tight lab follow-up.
The key word is “specific.” DAC as a default because it’s more convenient is, in my opinion, the wrong framing. DAC as a targeted tool for a defined situation is a different conversation entirely.
Either way, the decision belongs with a prescriber who’s going to follow your labs. Not a forum thread. Not this post.
Where I Source
I ran both DAC and no-DAC versions through compounding pharmacies under my doctor’s prescription. The no-DAC lots I’ve used most recently came through FormBlends CJC-1295 via a 503A compounding pharmacy in the network my prescriber uses. The lots are labeled with beyond-use dating, lot numbers, and a sterility statement on request, which I’ve asked for once and received without friction.
Other 503A pharmacies fill the same prescriptions. The question to ask your prescriber isn’t which website to order from. It’s which pharmacy they trust to compound your specific peptide protocol.
The Bottom Line
No-DAC for the default case. DAC for specific scenarios under tight prescriber monitoring. Both work. The pulse pattern matters more than most people think, and convenience is a lousy reason to compromise it.
Not FDA-approved. Compounded CJC-1295 in either form is prescribed and dispensed by licensed pharmacies for individual patient prescriptions based on clinical judgment. This is not medical advice.
Frequently Asked Questions
What is the main difference between CJC-1295 with DAC and without DAC? The peptide itself is identical. The DAC (drug affinity complex) modification allows reversible binding to serum albumin, which extends the half-life from roughly 30 minutes to 6 to 8 days. No-DAC clears quickly and supports a pulsatile GH pattern. DAC produces a sustained, week-long elevation in GH-releasing signal.
Is CJC-1295 with DAC more effective than without DAC? “Effective” depends on what you’re optimizing for. DAC tends to produce higher average IGF-1 levels and faster initial body composition changes, but it also comes with a higher incidence of fluid retention and a less natural GH release pattern. Over 12 months, my cumulative results on no-DAC matched or exceeded what I achieved on DAC in four months.
Why do some prescribers prefer no-DAC? Primarily because it preserves the body’s natural pulsatile GH release pattern, is easier to titrate (shorter half-life means faster dose adjustments), and carries a lower risk of fluid retention and related side effects.
Can you switch between DAC and no-DAC versions? Yes. My prescriber moved me from DAC to no-DAC after reviewing my 6-week labs. The transition was straightforward; I simply stopped the twice-weekly DAC injections and began nightly no-DAC plus ipamorelin dosing.
What side effects should I watch for on CJC-1295 with DAC? The most common early signal is fluid retention: ankle puffiness, morning hand stiffness, a general “puffy” feeling. Elevated IGF-1 beyond your prescriber’s target range is the lab marker to watch. These effects are dose-dependent and typically resolve with dose reduction or switching to no-DAC.
Is CJC-1295 FDA-approved? No. CJC-1295 in either form is not FDA-approved for any human indication. It is accessed through 503A compounding pharmacies under individual patient prescriptions based on a prescriber’s clinical judgment.
How often do you need to inject CJC-1295 without DAC? Typically 5 to 7 nights per week, often combined with ipamorelin in the same injection. The short half-life requires more frequent dosing than the DAC version, but the trade-off is a more physiological GH release pattern and easier dose management.
